It is well known that the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used to treat NSCLC patients clinically through blocking of intracellular receptor phosphorylation (38). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.